Temu accused by EU regulators of failing to prevent sale of illegal products
The preliminary findings follow an investigation opened last year under the bloc's Digital Services Act (DSA).
Advertisement
It is a wide-ranging rulebook that requires online platforms to do more to keep internet users safe, with the threat of hefty fines.
The European Commission, the 27-nation bloc's executive branch, said its investigation found 'a high risk for consumers in the EU to encounter illegal products' on Temu's site.
Investigators carried out a 'mystery shopping exercise' that found 'non-compliant' products on Temu, including baby toys and small electronics, it said.
Temu said in a brief statement that it 'will continue to co-operate fully with the commission'.
Advertisement
The commission did not specify why exactly the products were illegal, but noted that a surge in online sales in the bloc also came with a parallel rise in unsafe or counterfeit goods.
EU regulators said when they opened the investigation that they would look into whether Temu was doing enough to crack down on 'rogue traders' selling 'non-compliant goods' amid concerns that they are able to swiftly reappear after being suspended.
In its preliminary findings, the commission found that Temu could have had 'inadequate mitigation measures' because the company was using an 'inaccurate' risk assessment that relied on general industry information, rather than specifics about its own marketplace.
'We shop online because we trust that products sold in our single market are safe and comply with our rules,' Henna Virkkunen, the EU's executive vice-president for tech sovereignty, security and democracy, said in a news release.
Advertisement
'In our preliminary view, Temu is far from assessing risks for its users at the standards required by the Digital Services Act.'
Temu has grown in popularity by offering cheap goods – from clothing to home products – shipped from sellers in China.
The company, owned by Pinduoduo, a popular e-commerce site in China, has 92 million users in the EU.
The company will have the chance to examine the commission's investigation files and respond to the accusations before the EU watchdogs make a final decision.
Advertisement
Violations of the DSA could result in fines of up to 6% of a company's annual global revenue and an order to fix the problems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
34 minutes ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
The Sun
43 minutes ago
- The Sun
Future of chain Claire's on UK high streets uncertain after US parent firm files for bankruptcy
FASHION accessories chain Claire's is facing an uncertain future on UK high streets, after its US parent firm filed for bankruptcy. It is the second time the ear-piercing favourite has declared itself bust, after previously filing for bankruptcy in 2018. 1 Its finances are now under pressure from weak consumer demand and supply chain uncertainty. The filings showed that the parent business reported liabilities of up to $10billion (£7billion) and owed between 25,000 and 50,000 creditors. Claire's operates 2,750 stores worldwide, including 280 in the UK. While British stores remain unaffected for now, the UK arm has lost £25million over the past three years and is at risk of collapsing into administration later this month. It has been working with advisers to explore a sale or restructuring. However, potential buyers, such as Hilco Capital, are understood to have walked away. Retail experts say Claire's is struggling to stay relevant. Julie Palmer, from Begbies Traynor, said: 'Claire's low-price offering is clearly not strong enough to win over its core customers — teens and young adults — as they now have access to a vast array of affordable and convenient products online through platforms like Amazon and Temu.' Claire's boss Chris Cramer said: 'We remain in active discussions with potential strategic and financial partners and are committed to completing our review of strategic alternatives.' Nostalgic 90's retailer files for bankruptcy after chain misses rent payments for June and July 'CORE BLIMEY! MINING giant Glenciore has decided to stick with its London stock listing, scrapping plans to shift to New York, in a win for the City. It has been listed on the FTSE since 2011, when it was valued at £37billion — at the time the exchange's largest float. However, the Swiss-based firm has announced plans to slash £753million in costs by 2026, including job cuts across its 150,000-strong workforce. METRO BANK ON THE UP METRO BANK has bounced back, posting a £43.1million pre-tax profit for the first half of 2025 — up from a £33.5million loss reported in the same period last year. The lender doubled new corporate and small business loans to £1billion, and cut 8 per cent from its costs by axing a third of its workforce and reducing branch hours. Boss Daniel Frumkin said: 'Our strong performance reflects the decisive actions we have taken.' Elsewhere, Sabadell shareholders have approved the £2.65billion sale of TSB to Santander.
The Independent
an hour ago
- The Independent
Tory leader Kemi Badenoch says Josef Fritzl case made her ‘reject God'
Conservative leader Kemi Badenoch has revealed the case of Austrian sex offender Josef Fritzl caused her to lose faith in God. Mrs Badenoch said she was 'never that religious' while growing up but 'believed there was a God' and 'would have defined myself as a Christian apologist'. But this changed in 2008 when she read reports that Fritzl had imprisoned and repeatedly raped his daughter, Elisabeth, in his basement over 24 years. Mrs Badenoch, whose maternal grandfather was a Methodist minister, told the BBC: 'I couldn't stop reading this story. And I read her account, how she prayed every day to be rescued. 'And I thought, I was praying for all sorts of stupid things and I was getting my prayers answered. I was praying to have good grades, my hair should grow longer, and I would pray for the bus to come on time so I wouldn't miss something. 'It's like, why were those prayers answered and not this woman's prayers? And it just, it was like someone blew out a candle.' But she insisted that while she had 'rejected God', she had not rejected Christianity and remained a 'cultural Christian', saying she wanted to 'protect certain things because I think the world that we have in the UK is very much built on many Christian values'. During her interview, which is due to be broadcast on Thursday evening, Mrs Badenoch also said her tenure as Conservative leader was going 'well', adding her job was to 'make sure that people can see that we are the only party on the centre-right'. In an apparent dig at Nigel Farage's Reform UK, she said: 'There are pretenders. We're the only party on the centre-right, and we're the only ones who still believe in values like living within our means, personal responsibility, making sure that the government is not getting involved in everything so it can focus on the things it needs to look at, like securing our borders.' She went on to defend previous comments saying the fact she had worked at McDonald's made her working class, saying: 'I had to work to live. 'That, for me, is what being working class is. It's the lifestyle that you have. You have to work, to survive.' And she argued that parents who were 'worried about their children getting stolen or snatched' had created a younger generation that lacked the 'resilience' to deal with problems in life. Responding to figures suggesting a quarter of people aged 16-24 said they had a mental disorder, Mrs Badenoch said: 'I think they think they have a mental disorder, I don't think they all have a mental disorder.' She added: 'I'm not a medical expert so it is not my expertise on exactly what we need to do to get them into work, but we should be trying to get them into work.'
